Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab and Radiotherapy in Salivary Gland Cancer
NCT00984217Phase 2Withdrawn
- Sponsor
- University of Pittsburgh
- Start
- Aug 2011
- Primary completion
- Aug 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in salivary gland cancer (SGC), sponsored by University of Pittsburgh. Primary endpoint: Recurrence-Free Survival at 3 years. Planned start Aug 2011; status: withdrawn.
02
Drugs
panitumumab
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT00984217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984217.